Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18684596 | NOVEL COMPOUND AND USE OF SAID COMPOUND | February 2024 | February 2026 | Allow | 24 | 0 | 0 | No | No |
| 18260112 | HAIR CONDITIONER FORMULATION | June 2023 | March 2026 | Allow | 32 | 1 | 0 | No | No |
| 18200812 | METHODS OF OTOPROTECTION AGAINST PLATINUM-BASED ANTINEOPLASTIC AGENTS | May 2023 | February 2026 | Allow | 33 | 2 | 0 | No | No |
| 18199903 | COMBINED PHARMACEUTICAL FORMULATION COMPRISING GEMCITABINE-CONTAINING LIPOSOME COMPOSITION AND IMMUNE CHECKPOINT INHIBITOR | May 2023 | November 2025 | Abandon | 30 | 1 | 0 | No | No |
| 18025444 | HERBICIDAL COMBINATIONS COMPRISING DIFLUFENICAN AND MESOTRIONE | March 2023 | January 2026 | Allow | 34 | 1 | 1 | No | No |
| 18161356 | STABLE MICRONUTRIENT COMPLEX FOR USE IN AGRICULTURAL APPLICATIONS | January 2023 | March 2026 | Allow | 37 | 2 | 0 | No | No |
| 18101055 | TREATING MICROVASCULAR DYSFUNCTION | January 2023 | August 2025 | Allow | 31 | 2 | 0 | No | No |
| 18006617 | VISCOUS AQUEOUS COMPOSITION AND SKIN EXTERNAL PREPARATION | January 2023 | October 2025 | Allow | 33 | 2 | 0 | No | No |
| 18016672 | SOL-GEL CONVERSION OVER TIME OF 6-ARM PEG HYDROGEL | January 2023 | February 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18153467 | COMPOSITION FOR SUPPRESSING SKIN IRRITATION OR INHIBITING SEBUM SECRETION | January 2023 | November 2025 | Allow | 34 | 2 | 0 | Yes | No |
| 18096227 | METHOD AND PHARMACEUTICAL COMPOSITION FOR RESCUING RETINAL DEGENERATION | January 2023 | April 2025 | Allow | 27 | 1 | 0 | No | No |
| 18153514 | TOPICAL COMPOSITIONS FOR TREATING OR PREVENTING SCARS AND METHODS FOR THEIR USE | January 2023 | March 2026 | Abandon | 38 | 1 | 1 | No | No |
| 18094156 | Composition and Method for Preventing or Treating Opioid Withdrawal Symptoms | January 2023 | November 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 18093714 | HAIR COMPOSITE FOR HAIR THICKENING AND HAIR GROWTH | January 2023 | June 2025 | Abandon | 30 | 1 | 0 | No | No |
| 18069304 | Production of Silicate Solutions and their Uses | December 2022 | January 2026 | Allow | 37 | 2 | 1 | No | No |
| 18010752 | ACTIVE COMPOUND COMBINATIONS | December 2022 | February 2026 | Allow | 38 | 1 | 1 | No | No |
| 18009603 | NOVEL USE | December 2022 | September 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17922259 | COSMETIC COMPOSITION IN AEROSOL FORM, METHOD FOR PRODUCTION AND USE | October 2022 | July 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17997202 | USE OF POLYETHERS AS CARRIER FOR ACTIVE INGREDIENTS | October 2022 | November 2025 | Allow | 36 | 2 | 1 | Yes | No |
| 17918967 | STICK-TYPE OIL-DISPERSION COSMETIC COMPOSITION COMPRISING POWDER | October 2022 | November 2025 | Abandon | 37 | 2 | 0 | No | No |
| 17996150 | TERPENE-CONTAINING COMPOSITION AND ITS COSMETIC USE | October 2022 | August 2025 | Allow | 34 | 1 | 1 | No | No |
| 17918361 | PERSONAL CARE COMPOSITION WITH VISUALLY DISTINCT AQUEOUS AND OIL PHASE | October 2022 | February 2026 | Abandon | 40 | 2 | 1 | No | No |
| 18045818 | ENVIRONMENTALLY FRIENDLY LIQUID AND USES THEREOF | October 2022 | June 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17957402 | TAILORED LIPOSOMES FOR THE TREATMENT OF BACTERIAL INFECTIONS | September 2022 | December 2025 | Allow | 38 | 3 | 0 | Yes | No |
| 17954214 | COMPOSITIONS AND METHODS RELATING TO PIGMENTATION | September 2022 | October 2025 | Allow | 37 | 2 | 0 | Yes | No |
| 17755183 | BIODEGRADABLE STRETCH FILM | September 2022 | December 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17906326 | METHOD FOR PRODUCING PARTICLES | September 2022 | August 2025 | Allow | 35 | 2 | 0 | Yes | No |
| 17910244 | A PERSONAL CARE COMPOSITION | September 2022 | December 2025 | Allow | 39 | 1 | 1 | No | No |
| 17904664 | SELF-EMULSIFYING COMPOSITION, INTENDED FOR ADMINISTRATION ONTO THE SKIN, CONTAINING BIOSURFACTANT, COSURFACTANT AND OIL PHASE | August 2022 | March 2025 | Allow | 31 | 1 | 0 | No | No |
| 17882144 | LIPOSOME COMPOSITION AND PHARMACEUTICAL COMPOSITION | August 2022 | September 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17798064 | COMPOSITIONS OF ALUM NANOPARTICLES FOR IMMUNOMODULATION AND METHODS FOR PRODUCING THE SAME | August 2022 | September 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17831071 | Method for Preparing Transmembrane pH-Gradient Vesicles | June 2022 | June 2025 | Allow | 37 | 2 | 0 | No | No |
| 17824901 | DEVICES AND METHODS FOR THE TRANSDERMAL DELIVERY OF PSILOCYBIN | May 2022 | June 2025 | Abandon | 36 | 1 | 0 | Yes | No |
| 17753847 | WATER-IN-OIL EMULSIFIABLE FORMULATION CONTAINING A SULFOPOLYMER | March 2022 | October 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17680152 | On Demand Drug Release System | February 2022 | October 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17360927 | ZINC MELOXICAM COMPLEX MICROPARTICLES AND ANESTHETIC FORMULATIONS AND PROCESSES FOR MAKING THE SAME | June 2021 | August 2025 | Abandon | 50 | 1 | 0 | No | No |
| 17344039 | ZINC MELOXICAM COMPLEX MICROPARTICLE MULTIVESICULAR LIPOSOME FORMULATIONS AND PROCESSES FOR MAKING THE SAME | June 2021 | October 2025 | Allow | 52 | 3 | 0 | No | No |
| 17202278 | ROOT NODULE GROWTH-PROMOTING BACTERIUM MICROBACTERIUM SP. X-18 AND APPLICATION THEREOF | March 2021 | October 2025 | Abandon | 55 | 1 | 0 | No | No |
| 17274850 | SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING OF A SEDATIVE DRUG AND USES THEREOF | March 2021 | January 2026 | Allow | 58 | 4 | 1 | No | No |
| 16568801 | PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE OF WEAK ACID DRUGS AND USES THEREOF | September 2019 | August 2025 | Abandon | 60 | 9 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner VIGIL, TORIANA NICHOLE works in Art Unit 1612 and has examined 5 patent applications in our dataset. With an allowance rate of 40.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 55 months.
Examiner VIGIL, TORIANA NICHOLE's allowance rate of 40.0% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by VIGIL, TORIANA NICHOLE receive 3.60 office actions before reaching final disposition. This places the examiner in the 95% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by VIGIL, TORIANA NICHOLE is 55 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a -50.0% benefit to allowance rate for applications examined by VIGIL, TORIANA NICHOLE. This interview benefit is in the 0% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 16.7% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 0% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.